Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages

Journal of Natural Products

Volumn 61, Issue 10, 1998, Pages 1221-1225

  Harrigan, George G ^a   Yoshida, Wesley Y ^a   Moore, Richard E ^a   Nagle, Dale G ^b,f   Park, Peter U ^b   Biggs, Jason ^b   Paul, Valerie J ^b   Mooberry, Susan L ^c   Corbett, Thomas H ^d   Valeriote, Fred A ^e  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF GUAM MARINE LABORATORY   (Guam)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; DOLASTATIN; DOLASTATIN 12; LYNGBYASTATIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; COLON ADENOCARCINOMA; CYANOBACTERIUM; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL LINE; CYANOBACTERIA; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICROFILAMENTS; MOLECULAR STRUCTURE; OLIGOPEPTIDES;

ANIMALIA; CYANOBACTERIA; LYNGBYA MAJUSCULA; SCHIZOTHRIX CALCICOLA;

EID: 15144345966     PISSN: 01633864     EISSN: None     Source Type: Journal    
DOI: 10.1021/np9801211     Document Type: Article

References (13)

1. (1) Trimurtulu, G.; Ohtani, I.; Patterson, G. M. L.; Moore, R. E.; Corbett, T. H.; Valeriote, F. A.; Demchik, L. J. Am. Chem. Soc. 1994, 116, 4729-4737. Golakoti, T.; Ogino, J.; Heltzel, C. E.; Husebo, T. L.; Jensen, C. M.; Larsen, L. K.; Patterson, G. M. L.; Moore, R. E.; Mooberry, S. L.; Corbett, T. H.; Valeriote, F. A. J. Am. Chem. Soc. 1995, 117, 12030-12049. Moore, R. E.; Corbett, T. H.; Patterson, G. M. L.; Valeriote, F. A. Curr. Pharm. Design 1996, 2, 317-330.
2. Trimurtulu, G.; Ohtani, I.; Patterson, G. M. L.; Moore, R. E.; Corbett, T. H.; Valeriote, F. A.; Demchik, L. J. Am. Chem. Soc. 1994, 116, 4729-4737. Golakoti, T.; Ogino, J.; Heltzel, C. E.; Husebo, T. L.; Jensen, C. M.; Larsen, L. K.; Patterson, G. M. L.; Moore, R. E.; Mooberry, S. L.; Corbett, T. H.; Valeriote, F. A. J. Am. Chem. Soc. 1995, 117, 12030-12049. Moore, R. E.; Corbett, T. H.; Patterson, G. M. L.; Valeriote, F. A. Curr. Pharm. Design 1996, 2, 317-330.
3. Trimurtulu, G.; Ohtani, I.; Patterson, G. M. L.; Moore, R. E.; Corbett, T. H.; Valeriote, F. A.; Demchik, L. J. Am. Chem. Soc. 1994, 116, 4729-4737. Golakoti, T.; Ogino, J.; Heltzel, C. E.; Husebo, T. L.; Jensen, C. M.; Larsen, L. K.; Patterson, G. M. L.; Moore, R. E.; Mooberry, S. L.; Corbett, T. H.; Valeriote, F. A. J. Am. Chem. Soc. 1995, 117, 12030-12049. Moore, R. E.; Corbett, T. H.; Patterson, G. M. L.; Valeriote, F. A. Curr. Pharm. Design 1996, 2, 317-330.
4. (2) Gerwick, W. H.; Proteau, P. J.; Nagle, D. G.; Hamel, E.; Blokhin, A.; Slate, D. L. J. Org. Chem. 1994, 59, 1243-1245. Verdier-Pinard, P.; Lai, J.-Y.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Mol. Pharmacol. 1998, 53, 62-76.
5. Gerwick, W. H.; Proteau, P. J.; Nagle, D. G.; Hamel, E.; Blokhin, A.; Slate, D. L. J. Org. Chem. 1994, 59, 1243-1245. Verdier-Pinard, P.; Lai, J.-Y.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Mol. Pharmacol. 1998, 53, 62-76.
6. Corbett, T. H.; Valeriote, F. A.; Polin, L.; Panchapor, C.; Pugh, S.; White, K. Lowichik, N.; Knight, J.; Bissery, M.-C.; Wozniak, A.; LoRusso, P.; Biernat, L.; Polin, D.; Knight, L.; Biggar, S.; Looney, D.; Demchik, L.; Jones, J.; Jones, L.; Blair, S.; Palmer, K.; Essenmacher, S.; Lisow, L.; Mattes, K. C.; Cavanaugh, P. F.; Rake, J. B.; Baker, L. In Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development; Valeriote, F. A., Corbett, T. H., Baker, L. H. Eds.; Kluwer Academic Publishers: Norwell, 1993; pp 35-87.
7. Carter D. C.; Moore, R. E.; Mynderse, J. S.; Niemczura, W. P., Todd, J. S. J. Org. Chem. 1984, 49, 236-242.
8. Pettit G. R., Kamano, Y.; Kizu, H.; Dufresne, C.; Herald, C. L.; Bontems, R. J.; Schmidt, J. M.; Boettner, F. E.; Nieman, R. A. Heterocycles 1989, 28, 553-558.
9. Marfey, P. Carlsberg Res. Comm. 1984, 49, 591-596.
10. Bates, R. B.; Brusoe, K. G.; Burns, J. J.; Caldera, S.; Cui, W.; Gangwar, S.; Gramme, M. R.; McClure, K. J.; Rouen, G. P., Schadow, H.; Stessman, C. C.; Taylor, S. R.; Vu, V. H.; Yarick, G. V.; Zhang, J.; Pettit, G. R.; Bontems, R. J. Am. Chem. Soc. 1997, 119, 2111-2113.
11. (8) Kato, Y.; Scheuer, P. J. J. Am. Chem. Soc. 1974, 96, 2245-2246. Moore, R. E.; Blackman, A. J.; Cheuk, C. E.; Mynderse, J. E.; Matsumoto, G. K.; Clardy, J.; Woodward, R. W.; Craig, J. C. J. Org. Chem. 1984, 49, 2484-2489.
12. Kato, Y.; Scheuer, P. J. J. Am. Chem. Soc. 1974, 96, 2245-2246. Moore, R. E.; Blackman, A. J.; Cheuk, C. E.; Mynderse, J. E.; Matsumoto, G. K.; Clardy, J.; Woodward, R. W.; Craig, J. C. J. Org. Chem. 1984, 49, 2484-2489.
13. Corbett, T.; Vaeriote, F.; LoRusso, P.; Polin, L.; Panchapor, C.; Pugh, S.; White, K.; Knight, J.; Demchik, L.; Jones, J.; Jones, L.; Lisow, L. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval; Teicher, B., Ed.; Humana Press Inc.: Totowa, NJ, 1997; pp 75-99.